Incyte Genomics Appoints Barry Ariko, Chairman and Chief Executive Officer of Extricity Software, Inc., to Board of Directors Palo Alto, CA, April 5, 2001 -- Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, today announced the appointment of Barry Ariko to its Board of Directors. Barry has more than 30 years of senior executive-level experience with industry-leading corporations, including Netscape Communications Corp., Oracle Corp., and Tandem Computers, Inc. Barry is currently Chairman and Chief Executive Officer of Extricity Software, Inc. Before joining Extricity, Barry served as Senior Vice President of the Netscape Enterprise Group at America Online, Inc. from March 1999 to January 2000, where Barry was responsible for Netscape's worldwide sales, strategic partnerships, professional services and support services, and as Executive Vice President and Chief Operating Officer of Netscape from 1998 to 1999. From 1994 to 1998, Barry served as Executive Vice President and member of the Executive Management Committee at Oracle. In this position, Barry headed Oracle's Americas operations. He was responsible for global sales practices, and was credited with helping the company achieve much of the growth in its Americas operation- Oracle's largest business unit. During his tenure, the organization grew into a multi-billion dollar operation. Prior to Oracle, Barry served at Tandem Computers for 13 years in various executive management roles. "We are pleased that Mr. Ariko will be joining our Board of Directors," said Roy A. Whitfield, Chief Executive Officer of Incyte. "Information Technology is at the core of Incyte's business and Barry brings to Incyte years of proven executive experience managing profitable and cutting-edge IT businesses." In addition to his Board seat at Extricity, he also serves on the Board of Directors of Autonomy Corporation plc (Nasdaq: AUTN;LSE: AU; Easdaq: AUTN) based in Cambridge, England and of Rulespace, Inc., a privately owned company based in Portland, Oregon. Mr. Ariko will also serve on the Board of Directors for Peregrine Systems, Inc. (Nasdaq:PRGN) upon the acquisition close of Extricity. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including utilization of the databases and other products, programs and services in pharmaceutical and biotechnology research and development; the impact of technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2000. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements.